Clinical Trial Update: A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial investigates whether adding valemetostat tosylate to pembrolizumab improves outcomes compared with pembrolizumab alone in first-line non-sma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Valemetostat Tosylate (valemetostat tosylate)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-small Cell Lung Cancer, Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING